Albenatide vs Visepegenatide (PB-119)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
Albenatide
Developed by ConjuChem and partners
NCT07058545 · Phase 3 · completed
The study randomized 474 participants to CJC-1134-PC or placebo and blinded participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in HbA1c at Week 25, a surrogate measure, and the registry does not report whether the comparison was favorable or statistically significant.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
No aligned efficacy figure on record for this race.
Visepegenatide (PB-119)
Marketed by PegBio
NCT04504396 · Phase 3 · completed
This randomized, placebo-controlled trial kept participants, care providers, investigators and outcome assessors blind to treatment assignment. Its primary endpoint, change in HbA1c, was clearly met, with PB-119 producing a significantly larger reduction than placebo (P<0.001).
Reported efficacy
Change in HbA1c (week 1, week 25): Change in HbA1c from baseline: -1.25% (95% CI -1.35 to -1.16) with visepegenatide (PB-119) vs -0.68% (95% CI -0.78 to -0.59) with placebo; treatment difference -0.57% (95% CI -0.71 to -0.43), p<0.001. (met)
Result source: NCT04504396
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Albenatide | Visepegenatide (PB-119) |
|---|---|---|
| HbA1c, change | -0.8% vs -0.5%−0.4 vs placeboNCT006387161 other result
| -1.4% vs -0.6%a−0.7 vs placeboNCT045043701 other result
|
| Body weight, change (kg) | -2.0 vs -1.6−0.4 vs placeboNCT006387161 other result
| —Not posted · NCT04504396 |
| HbA1c below 7% | —Not posted · NCT07058545 | —Not posted · NCT04504396 |
| Fasting plasma glucose, change | -0.8 vs -0.6−0.2 vs placeboNCT006387161 other result
| —Not posted · NCT04504396 |
| 3-point MACE (% with event) | —Not posted · NCT07058545 | —Not posted · NCT04504396 |
HbA1c, change
- Albenatide
- -0.8% vs -0.5%−0.4 vs placeboNCT00638716
1 other result
- -1.3% vs -0.3% NCT00674466
- Visepegenatide (PB-119)
- -1.4% vs -0.6%a−0.7 vs placeboNCT04504370
1 other result
- -1.3% vs -0.7% NCT04504396
Body weight, change (kg)
- Albenatide
- -2.0 vs -1.6−0.4 vs placeboNCT00638716
1 other result
- -1.2 vs -0.4 NCT00674466
- Visepegenatide (PB-119)
- —Not posted · NCT04504396
HbA1c below 7%
- Albenatide
- —Not posted · NCT07058545
- Visepegenatide (PB-119)
- —Not posted · NCT04504396
Fasting plasma glucose, change
- Albenatide
- -0.8 vs -0.6−0.2 vs placeboNCT00638716
1 other result
- -0.3 vs 0.7 NCT00674466
- Visepegenatide (PB-119)
- —Not posted · NCT04504396
3-point MACE (% with event)
- Albenatide
- —Not posted · NCT07058545
- Visepegenatide (PB-119)
- —Not posted · NCT04504396
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Albenatide: 3 of 4 rows · Visepegenatide (PB-119): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Albenatide | Visepegenatide (PB-119) |
|---|---|---|
| Dropout rate | 14%1.5 mga NCT00638716 · Phase 2 · registry result, not featured evidence show 1 more result23.3%1.5 mg NCT00674466 · Phase 2 · registry result, not featured evidence | — |
| Discontinued due to AEs | —1.5 mga NCT00638716 · Phase 2 · registry result, not featured evidence show 1 more result—1.5 mg NCT00674466 · Phase 2 · registry result, not featured evidence | — |
| Serious AEs | 0%1.5 mga NCT00638716 · Phase 2 · registry result, not featured evidence show 1 more result3.3%1.5 mg NCT00674466 · Phase 2 · registry result, not featured evidence | — |
| Most frequent reported AEs | 1.5 mga nausea 22.4% (placebo 15.8%) diarrhea 12.2% (placebo 5.3%) vomiting 12.2% (placebo 3.5%) NCT00638716 · Phase 2 · registry result, not featured evidence show 1 more result1.5 mg headache 26.7% (placebo 24.1%) nausea 26.7% (placebo 13.8%) vomiting 23.3% (placebo 17.2%) NCT00674466 · Phase 2 · registry result, not featured evidence | — |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Albenatide
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Albenatide's landscape · Visepegenatide (PB-119)'s landscape